万维提示：
1、投稿方式：在线投稿。
2、期刊网址：
https://journals.lww.com/behaviouralpharm/pages/default.aspx
3、投稿网址：https://www.editorialmanager.com/bpharm/
4、官网邮箱：如下。
5、官网电话：+44-(0)1792 295844（编辑）
6、期刊刊期：一年出版8期。
2021年8月11日星期三
期刊邮箱【官网信息】
Editorial Board
Editor
Professor Louk Vanderschuren
L.J.M.J.Vanderschuren@uu.nl
Associate Editors
Dr Emily M. Jutkiewicz
ejutkiew@umich.edu
Dr Paul Willner
Phone: +44-(0)1792 295844
Fax: +44-(0)1792 295679
p.willner@swansea.ac.uk
Reviews Editor
Bart Ellenbroek
bart.ellenbroek@vuw.ac.nz
Assistant Editors – Reviews
Gernot Riedel
g.riedel@abdn.ac.uk
Viviana Trezza
viviana.trezza@uniroma3.it
Benjamin Yee
benjamin.yee@polyu.edu.hk
投稿须知【官网信息】
Guidance for Authors on the Preparation and Submission of Manuscripts to Behavioural Pharmacology
Note: These instructions comply with those formulated by the International Committee of Medical Journal Editors. For further details, authors should consult the "Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals" www.icmje.org.
The Journal is a member of the Committee on Publication Ethics (COPE) which aims to define best practice in the ethics of scientific publishing. COPE has established a number of guidelines as part of a set of Core Practices (www.publicationethics.org).
Appeals on editorial decisions should be sent to the Editor. Complaints related to how your paper was processed during peer-review and not resolved by the Editor, should be referred to the person named as publisher in "About the Journal" under "Journal Info" contacts (http://journals.lww.com/behaviouralpharm/Pages/aboutthejournal.aspx) or if unsatisfied to COPE (www.publicationethics.org).
This Journal allows authors to choose an Open Access option for their published article on payment of a fee. See the Open Access section below.
SCOPE
Behavioural Pharmacology accepts original full and short research reports in diverse areas ranging from ethopharmacology to the pharmacology of schedule-controlled operant behaviour, provided that their primary focus is behavioural. Suitable topics include drug, chemical and hormonal effects on behaviour, the neurochemical mechanisms under-lying behaviour, and behavioural methods for the study of drug action. Both animal and human studies are welcome; however, studies reporting neurochemical data should have a predominantly behavioural focus, and human studies should not consist exclusively of clinical trials or case reports. Preference is given to studies that demonstrate and develop the potential of behavioural methods, and to papers reporting findings of direct relevance to clinical problems. Papers making a significant theoretical contribution are particularly welcome and, where possible and merited, space is made available for authors to explore fully the theoretical implications of their findings. Reviews of an area of the literature or at an appropriate stage in the development of an author’s own work are welcome. Commentaries in areas of current interest are also considered for publication, as are Reviews and Commentaries in areas outside behavioural pharmacology, but of importance and interest to behavioural pharmacologists. Behavioural Pharmacology publishes frequent Special Issues on current hot topics. The editors welcome correspondence about whether a paper in preparation might be suitable for inclusion in a Special Issue.
SUBMISSIONS
Authors are strongly encouraged to submit their manuscripts through the web-based tracking system at http://www.editorialmanager.com/bpharm/default.aspx. The site contains instructions and advice on how to use the system. Authors should NOT in addition then post a hard copy submission to the editorial office. Editor contact e-mails: Professor Emily Jutkiewicz, ejutkiew@umich.edu; Professor Louk Vanderschuren,: l.j.m.j.vanderschuren@uu.nl; Professor Paul Willner, p.willner@swansea.ac.uk. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editor and/or other editors and selected reviewers. Peer-review is single blind.
Double spacing should be used throughout the manuscript, which should include the following sections, each starting on a separate page: Title Page, abstract and keywords, text, acknowledgements, references, individual tables and captions. Margins should be not less than 3 cm. Pages should be numbered consecutively, beginning with the Title Page, and the page number should be placed in the top right-hand corner of each page. Abbreviations should be defined on their first appearance in the text; those not accepted by international bodies should be avoided.
Non-native speakers of English: Authors who are not native speakers of English and require help in writing an article in English are encouraged to seek assistance from a qualified colleague or consider using a language service in preparing a manuscript submission. Wolters Kluwer, in partnership with Editage, offers such services - for more information please visit http://wkauthorservices.editage.com. Please note that the use of this or other services are at the author's own expense and risk, and independent from the editorial processes of this journal, and does not guarantee that an article will be accepted for publication.
Article Types
Research Reports
Research reports should present original work that represents a significant scientific advance in the field of behavioural pharmacology. Manuscripts will be considered on the basis of the clarity of presentation and interest to the scientific community; results must be supported by appropriate data analysis including full inferential statistics (e.g. F, df1, df2, p). There is no limit on length or the number of tables and figures, but authors should strive to keep all of these to the minimum needed to convey the necessary information.
Short Reports
The Short Report format is reserved for limited data sets presenting unexpected or novel findings that will be of interest to the scientific community; results must be supported by appropriate data analysis including inferential statistics. Maximum 2500 words and two figures and/or tables. The word count may, if necessary, be exceeded; the 2 figure/table limit may not.
Reviews
The Editors are happy to discuss the suitability of topics. There is an indicative limit of 7500 words but this can be exceeded if the topic merits a longer discussion.
Commentaries
Maximum 2500 words
POINTS TO CONSIDER WHEN SUBMITTING YOUR PAPER TO ONE OF OUR JOURNALS
Please think carefully about the following points and make the appropriate declarations.
Redundant or duplicate publication
We ask you to confirm that your paper has not been published in its current form or a substantially similar form (in print or electronically, including on a web site), that it has not been accepted for publication elsewhere, and that it is not under consideration by another publication. The International Committee of Medical Journal Editors has provided details of what is and what is not duplicate or redundant publication (www.icmje.org). If you are in doubt (particularly in the case of material that you have posted on a web site, or an abstract of your work), we ask you to proceed with your submission but to include a copy of the relevant previously published work or work under consideration by other journals. In your covering letter to the editors, draw attention to any published work that concerns the same patients or subjects as the present paper.
Preprints: Work posted on a preprint server, which identifies a preprint as not peer-reviewed, will be considered for publication. The author should declare preprint server deposition on submitting their article to the Journal. If the article is accepted, to ensure readers can find and cite the final published version, authors should add the Digital Object Identifier (DOI) of the published journal article to the posted preprint version. Conflicts of interest
Authors must state all possible conflicts of interest in the manuscript, including financial, consultant, institutional and other relationships that might lead to bias or a conflict of interest. If there is no conflict of interest, this should also be explicitly stated as none declared. All sources of funding should be acknowledged in the manuscript. All relevant conflicts of interest and sources of funding should be included on the title page of the manuscript with the heading “Conflicts of Interest and Source of Funding:”. For example:
Conflicts of Interest and Source of Funding: A has received honoraria from Company Z. B is currently receiving a grant (#12345) from Organization Y, and is on the speaker’s bureau for Organization X – the CME organizers for Company A. For the remaining authors none were declared.
In Addition, each author must complete and submit the journal's copyright transfer agreement, which includes a section on the disclosure of potential conflicts of interest based on the recommendations of the International Committee of Medical Journal Editors, "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (www.icmje.org/update.html). The copyright agreement is included in the Author Questionnaire, completed by the submitting author within the Editorial Manager submission process. Co-authors will automatically receive an Email with a link to the questionnaire upon submission.
Permissions to reproduce previously published material
Authors must obtain prior submission copies of written permission to reproduce material published elsewhere (such as illustrations) from the copyright holder. The granting of permission should be acknowledged alongside the material (e.g., legend of a figure) in the submitted article. Authors are responsible for paying any fees to reproduce material.
Subject consent
Subjects have a right to privacy that should not be infringed without informed consent. Informed consent should be obtained from patients or other subjects of experiments that clearly grants permission for the publication of photographs or other material that might identify them. If the consent form for your research did not specifically include this, please obtain it or remove the identifying material. Identifying details (written or photographic) should be omitted if they are not essential, but patient data should never be altered or falsified in an attempt to attain anonymity. Complete anonymity is difficult to achieve. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. When informed consent has been obtained it should be indicated in the submitted article.
Ethics committee approval
You must state clearly in your submission in the Methods section that you conducted studies on human participants with the approval of an appropriate named ethics committee. Please also look at the latest version of the Declaration of Helsinki (www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/). Similarly, you must confirm that experiments involving animals adhered to ethical standards and must state the care of animal and licensing guidelines under which the study was performed.
The editors will welcome the submission of work in any area of behavioural pharmacology. However, studies that subject animals to pain or stress require special consideration and three principles will be used to judge the ethics of such work. First, experiments of this kind will be required to reach a higher threshold of scientific quality in order to be publishable. Second, the utility of the study will be addressed, in terms of the balance between the distress inflicted and the likelihood of benefit. Third, it must be demonstrated that the objectives of the experiment could not have been achieved by the use if less stressful procedures; the fact that a particular procedure has been used in previously published work will not in itself suffice. The editors believe that behavioural pharmacologists apply strict ethical criteria to their work, and will have no difficulty in meeting these requirements.
Clinical trial registration and data sharing
Behavioural Pharmacology does not usually publish clinical trials, but they may sometimes be accepted, particularly in the context of a Special Issue. As a condition for publication registration of a trial in a public registry is required. Registration of a trial must be at or before the enrolment of participants. The Editor does not advocate a particular registry but requires the registry meets the criteria set out in the statement of policy of the International Committee of Medical Journal Editors (www.icmje.org).
Clinical trials papers must contain a data sharing statement on whether data is available or not as outlined in the International Committee of Medical Journal Editors policy (www.icmje.org). A data sharing plan must be included in a trial's registration for those that begin enrolling participants on or after 1 January 2019. Authors of secondary analyses using shared data must reference the source of the data and attest their use was in accordance with any terms agreed.
Authorship
All authors must acknowledge that they have read and approved the paper, that they have met the criteria for authorship as established by the International Committee of Medical Journal Editors, that they believe that the paper represents honest work, and that they are able to verify the validity of the results reported. In addition to those from the ICJME the International Society for Medical Publication Professionals, ISMPP (www.ismpp.org) have produced some useful guidelines on authorship of studies sponsored by companies: Good Publication Practice (GPP3) (http://www.ismpp.org/gpp3).
Compliance with NIH and Other Research Funding Agency Accessibility Requirements
A number of research funding agencies now require or request authors to submit the post-print (the article after peer review and acceptance but not the final published article) to a repository that is accessible online by all without charge. As a service to our authors, LWW will identify to the National Library of Medicine (NLM) articles that require deposit and will transmit the post-print of an article based on research funded in whole or in part by the National Institutes of Health, Wellcome Trust, Howard Hughes Medical Institute, or other funding agencies to PubMed Central. The Copyright Transfer Agreement provides the mechanism.
Copyright assignment
Papers are accepted for publication on the understanding that exclusive copyright in the paper is assigned to the Publisher. Authors are asked to complete the online form during the submission process. They may use material from their paper in other works published by them after seeking formal permission.
Open access
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual unrestricted online access to their published article to readers globally, immediately upon publication. Authors may take advantage of the open access option at the point of acceptance to ensure that this choice has no influence on the peer review and acceptance process. These articles are subject to the journal's standard peer-review process and will be accepted or rejected based on their own merit.
The article processing charge (APC) is charged on acceptance of the article and should be paid within 30 days by the author, funding agency or institution. Payment must be processed for the article to be published open access. For a list of journals and pricing please visit our Wolters Kluwer Open Health Journals page.
Authors retain copyright
Authors retain their copyright for all articles they opt to publish open access. Authors grant Wolters Kluwer an exclusive license to publish the article and the article is made available under the terms of a Creative Commons user license. Please visit our Open Access Publication Process page for more information.
Creative Commons license
Open access articles are freely available to read, download and share from the time of publication under the terms of the Creative Commons License Attribution-NonCommerical No Derivative (CC BY-NC-ND) license. This license does not permit reuse for any commercial purposes nor does it cover the reuse or modification of individual elements of the work (such as figures, tables, etc.) in the creation of derivative works without specific permission.
Compliance with funder mandated open access policies
An author whose work is funded by an organization that mandates the use of the Creative Commons Attribution (CC BY) license is able to meet that requirement through the available open access license for approved funders. Information about the approved funders can be found here: http://www.wkopenhealth.com/inst-fund.php
FAQ for open access
http://www.wkopenhealth.com/openaccessfaq.php
Presentation of papers
Title Page
The Title Page should carry the full title of the paper and a short title, of no more than 40 characters and spaces, to be used as a 'running head' (and which should be so identified). The given or first name, middle initial and family name (surname) of each author should appear. The family name (surname) must appear in CAPITAL letters. If the work is to be attributed to a department or institution, its full name should be included. Any disclaimers should appear on the Title Page, as should the name and address of the author responsible for correspondence concerning the manuscript and the name and address of the author to whom requests for reprints should be made. Finally, the Title Page should state conflicts of interest and source of funding, and when none state “none declared”.
Abstracts
The second page should carry a abstract of no more than 250 words. The abstract should state the Objective(s) of the study or investigation, basic Methods (selection of study subjects or laboratory animals; observational and analytical methods), main Results (giving specific data), and the principal Conclusions. It should emphasise new and important aspects of the study or observations.
Key Words
The abstract should be followed by a list of 3–10 keywords or short phrases which will assist the cross-indexing of the article and which may be published. When possible, the terms used should be from the Medical Subject Headings list of the National Library of Medicine (http:// www.nlm.nih.gov/mesh/meshhome.html).
Text
Full papers of an experimental or observational nature should usually be divided into sections headed Introduction, Methods (including ethical and statistical information), Results and Discussion (including a conclusion), although reviews will likely require a different format.
Acknowledgements
Acknowledgements should be made only to those who have made a substantial contribution to the study. Authors are responsible for obtaining written permission from people acknowledged by name in case readers infer their endorsement of data and conclusions.
……
更多详情：
https://edmgr.ovid.com/bpharm/accounts/ifauth.htm
